Feb 19, 2024, 08:40 by

Feb 16, 2024, 09:04 by

Clinical Trial Media is Responsible for Identifying, Recruiting and Contributing Over 45% of Participants Across Multiple High-Demand Trials

Feb 15, 2024, 15:21 by User Not Found

Clinical Research News | SCOPE Summit 2024 once again shined a spotlight on the breakthroughs, discoveries, and achievements of hundreds of organizations in their efforts to improve clinical trials and help patients worldwide. Three awards were presented at the conference: the Participant Engagement Award, the Site Innovation Award, and the Best of Show Award.

Feb 15, 2024, 08:52 by

Feb 15, 2024, 08:52 by

HEPA-10X mitigates the spread of infection in high-risk healthcare environments

Feb 15, 2024, 08:52 by

PrecisionLife and Metrodora Institute are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more.

Feb 14, 2024, 09:04 by

uMed, the health and research technology company has played a crucial role in expanding the participant base of PREDICT-PD - a joint studybetween Queen Mary University of London and University College London (UCL), and funded by Parkinson’s UK investigating the onset and early stages of Parkinson's disease

Feb 14, 2024, 09:04 by

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Feb 13, 2024, 01:00 by User Not Found

Clinical Research News | Researchers from the University of Adelaide (Australia) and the Columbia University (New York) have “reimagined” osteoarthritis, providing a pharmaceutical target for the discovery of drugs to reverse and treat the ubiquitous degenerative joint disease. Osteoarthritis was originally believed to be a “wear and tear” condition, and some people still refer to it that way, which wrongly implies that its progression is a matter of time and inevitable.

Feb 12, 2024, 11:57 by User Not Found

Clinical Research News | The days leading up to the Summit for Clinical Ops Professionals—SCOPE—are a busy time for the clinical trials and clinical research space. The event kicked off yesterday and so far we’ve gathered these company and product news.

Feb 9, 2024, 09:15 by

Abzena launches LabZient™, an analytical platform accelerating antibody development timelines by combining predictive in-silico evaluation with laboratory methods. LabZient™ streamlines assessment, reduces costs, and enables early measurement of critical quality attributes. Fit-for-purpose across various antibody types, including mAbs and ADCs, LabZient™ enhances efficiency in biopharma development.

Feb 9, 2024, 09:15 by

Feb 8, 2024, 08:18 by

About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Media Contact Claire Kim, Head of Marketing Communications cair.kim@samsung.com About LegoChem Biosciences, Inc. LegoChem Biosciences (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies. For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e LegoChem Biosciences Media Contact Daeyoung Jeong, Team Leader of IR/BD jdy@legochembio.com

Feb 8, 2024, 08:18 by

Feb 8, 2024, 01:00 by User Not Found

Clinical Research News | In a big advance for precision medicine, researchers in Australia have developed a genetic biomarker of people’s response to sodium reduction. It is often but not always the case that modifying sodium levels lowers blood pressure by reducing the fluid volume of blood in the cardiovascular system, and knowing in advance how patients will respond could help eliminate the “treatment odyssey” that many of them are experiencing.

Feb 7, 2024, 14:02 by User Not Found

Clinical Research News | Dozens of companies are showcasing new products at next week’s Summit for Clinical Ops Executives, and 37 have been named finalists in the Best of Show People’s Choice Awards. The SCOPE community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year. Winners will be announced at the event on Tuesday, February 13.

Feb 7, 2024, 08:08 by

Feb 7, 2024, 08:08 by

Feb 7, 2024, 08:08 by

Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints RBQM Leader Shortlisted for Accolade for Innovation in the Management of Clinical Data

Feb 6, 2024, 09:01 by

Quantify Research has announced the opening of its new office today in Helsinki, Finland.